Any cancer-related discovery is essential to consider especially considering the nature of this unforgoving disease Recent ...

IMMvention is moving BACH1 inhibitors through preclinical development. The oral small molecules could induce fetal hemoglobin expression. Other companies have hit on the idea of treating sickle ...

BACH1 is thought to be a key regulator of cellular responses, oxidative stress, and inflammation in multiple disease states, making it a promising therapeutic target.

IMMvention over the past few years has focused on pursuing an oral therapy for sickle cell disease by targeting a specific protein, called BACH1, involved in sickle cell and other diseases.

FANCJ, also known as BACH1 or BRIP1, was identified as a direct BRCA1-BRCT interacting protein and functions in DNA repair and checkpoint control. Bi-allelic inheritance of mutations in FANCJ ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

The collaboration will leverage IMMvention’s investigational small-molecule Bach1 inhibitors. Bach1 is thought to be a key regulator of cellular responses, oxidative stress, and inflammation in ...

Furthermore, we observe differential expression of several transcription factors associated with energy metabolism and redox balance namely APE1/Ref-1, FOXO1, TIGAR and BACH1. The differentially ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.